LGND logo

LGND Total liabilities

annual total liabilities:

$111.33M+$25.03M(+29.00%)
December 31, 2024

Summary

  • As of today (June 2, 2025), LGND annual total liabilities is $111.33 million, with the most recent change of +$25.03 million (+29.00%) on December 31, 2024.
  • During the last 3 years, LGND annual total liabilities has fallen by -$365.10 million (-76.63%).
  • LGND annual total liabilities is now -84.70% below its all-time high of $727.68 million, reached on December 31, 2019.

Performance

LGND Total liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLGNDbalance sheet metrics

quarterly total liabilities:

$109.90M-$1.43M(-1.29%)
March 31, 2025

Summary

  • As of today (June 2, 2025), LGND quarterly total liabilities is $109.90 million, with the most recent change of -$1.43 million (-1.29%) on March 31, 2025.
  • Over the past year, LGND quarterly total liabilities has increased by +$2.55 million (+2.38%).
  • LGND quarterly total liabilities is now -92.18% below its all-time high of $1.41 billion, reached on September 30, 2018.

Performance

LGND quarterly total liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLGNDbalance sheet metrics

Total liabilities Formula

Total Liabilities = Current Liabilities + Long-Term Liabilities

LGND Total liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+29.0%+2.4%
3 y3 years-76.6%-64.8%
5 y5 years-84.7%-79.0%

LGND Total liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-76.6%+29.0%-64.8%+27.3%
5 y5-year-84.7%+29.0%-83.2%+27.3%
alltimeall time-84.7%+445.8%-92.2%+1405.5%

LGND Total liabilities History

DateAnnualQuarterly
Mar 2025
-
$109.90M(-1.3%)
Dec 2024
$111.33M(+29.0%)
$111.33M(-2.1%)
Sep 2024
-
$113.69M(+24.6%)
Jun 2024
-
$91.21M(-15.0%)
Mar 2024
-
$107.35M(+24.4%)
Dec 2023
$86.30M(-47.8%)
$86.30M(-14.8%)
Sep 2023
-
$101.33M(+8.7%)
Jun 2023
-
$93.21M(-43.4%)
Mar 2023
-
$164.76M(-0.3%)
Dec 2022
$165.18M(-65.3%)
$165.18M(-29.5%)
Sep 2022
-
$234.31M(-14.5%)
Jun 2022
-
$273.92M(-12.2%)
Mar 2022
-
$311.99M(-34.5%)
Dec 2021
$476.43M(-27.0%)
$476.43M(+3.2%)
Sep 2021
-
$461.59M(-1.7%)
Jun 2021
-
$469.77M(-14.5%)
Mar 2021
-
$549.28M(-15.9%)
Dec 2020
$652.76M(-10.3%)
$652.76M(+18.8%)
Sep 2020
-
$549.63M(+0.3%)
Jun 2020
-
$547.93M(+4.6%)
Mar 2020
-
$524.02M(-28.0%)
Dec 2019
$727.68M(+4.0%)
$727.68M(+4.4%)
Sep 2019
-
$696.89M(-8.3%)
Jun 2019
-
$760.38M(-8.8%)
Mar 2019
-
$834.01M(+19.2%)
Dec 2018
$699.89M(+177.3%)
$699.89M(-50.2%)
Sep 2018
-
$1.41B(+13.5%)
Jun 2018
-
$1.24B(+381.0%)
Mar 2018
-
$257.49M(+2.0%)
Dec 2017
$252.37M(+9.4%)
$252.37M(+6.2%)
Sep 2017
-
$237.57M(+3.0%)
Jun 2017
-
$230.62M(-0.1%)
Mar 2017
-
$230.94M(+0.1%)
Dec 2016
$230.73M(+2.0%)
$230.73M(+0.1%)
Sep 2016
-
$230.47M(+2.5%)
Jun 2016
-
$224.88M(+1.6%)
Mar 2016
-
$221.36M(-2.1%)
Dec 2015
$226.15M(-3.2%)
$226.15M(-1.5%)
Sep 2015
-
$229.52M(-2.6%)
Jun 2015
-
$235.71M(+2.1%)
Mar 2015
-
$230.83M(-1.2%)
Dec 2014
$233.62M(+324.0%)
$233.62M(+1.8%)
Sep 2014
-
$229.50M(+524.3%)
Jun 2014
-
$36.76M(-9.2%)
Mar 2014
-
$40.47M(-26.6%)
Dec 2013
$55.10M(-29.2%)
$55.10M(-3.1%)
Sep 2013
-
$56.86M(-5.7%)
Jun 2013
-
$60.30M(-11.0%)
Mar 2013
-
$67.77M(-12.9%)
Dec 2012
$77.78M(-30.8%)
$77.78M(+2.0%)
Sep 2012
-
$76.27M(-11.5%)
Jun 2012
-
$86.14M(-6.9%)
Mar 2012
-
$92.56M(-17.7%)
Dec 2011
$112.40M(+39.8%)
$112.40M(-6.4%)
Sep 2011
-
$120.10M(-1.6%)
Jun 2011
-
$122.11M(-5.4%)
Mar 2011
-
$129.14M(+60.6%)
Dec 2010
$80.41M(-41.8%)
$80.41M(-34.1%)
Sep 2010
-
$122.01M(-2.3%)
Jun 2010
-
$124.94M(-5.0%)
Mar 2010
-
$131.47M(-4.8%)
Dec 2009
$138.06M
$138.06M(+9.1%)
DateAnnualQuarterly
Sep 2009
-
$126.58M(-10.5%)
Jun 2009
-
$141.44M(-8.3%)
Mar 2009
-
$154.28M(-15.1%)
Dec 2008
$181.81M(+26.1%)
$181.81M(+25.2%)
Sep 2008
-
$145.24M(+3.0%)
Jun 2008
-
$141.00M(-0.5%)
Mar 2008
-
$141.73M(-1.7%)
Dec 2007
$144.16M(-51.7%)
$144.16M(-22.2%)
Sep 2007
-
$185.23M(-4.6%)
Jun 2007
-
$194.24M(-57.3%)
Mar 2007
-
$455.06M(+52.3%)
Dec 2006
$298.70M(-29.7%)
$298.70M(-38.2%)
Sep 2006
-
$483.06M(-7.9%)
Jun 2006
-
$524.43M(+2.2%)
Mar 2006
-
$513.05M(+20.7%)
Dec 2005
$425.04M(+4.2%)
$425.04M(+2.6%)
Sep 2005
-
$414.46M(+2.6%)
Jun 2005
-
$404.11M(-0.8%)
Mar 2005
-
$407.21M(-0.1%)
Dec 2004
$407.78M(+16.0%)
$407.78M(+64.6%)
Sep 2004
-
$247.70M(+4.4%)
Jun 2004
-
$237.32M(+1.5%)
Mar 2004
-
$233.82M(-33.5%)
Dec 2003
$351.60M(+74.6%)
$351.60M(+67.3%)
Sep 2003
-
$210.20M(+5.2%)
Jun 2003
-
$199.88M(-1.6%)
Mar 2003
-
$203.15M(+0.9%)
Dec 2002
$201.41M(+14.9%)
$201.41M(+439.1%)
Sep 2002
-
$37.36M(-8.1%)
Jun 2002
-
$40.65M(-53.8%)
Mar 2002
-
$87.88M(-49.9%)
Dec 2001
$175.35M(+4.0%)
$175.35M(+3.7%)
Sep 2001
-
$169.14M(-0.7%)
Jun 2001
-
$170.33M(+3.6%)
Mar 2001
-
$164.45M(-2.4%)
Dec 2000
$168.55M(+5.2%)
$168.55M(+16.0%)
Sep 2000
-
$145.35M(-0.3%)
Jun 2000
-
$145.80M(+2.5%)
Mar 2000
-
$142.20M(-11.2%)
Dec 1999
$160.20M(-4.3%)
$160.20M(-9.3%)
Sep 1999
-
$176.70M(+15.0%)
Jun 1999
-
$153.60M(+1.7%)
Mar 1999
-
$151.10M(-9.7%)
Dec 1998
$167.40M(+129.0%)
$167.40M(+41.4%)
Sep 1998
-
$118.40M(+72.6%)
Jun 1998
-
$68.60M(+2.8%)
Mar 1998
-
$66.70M(-8.8%)
Dec 1997
$73.10M(+8.1%)
$73.10M(+18.3%)
Sep 1997
-
$61.80M(-4.5%)
Jun 1997
-
$64.70M(+1.4%)
Mar 1997
-
$63.80M(-5.6%)
Dec 1996
$67.60M(+3.2%)
$67.60M(+14.4%)
Sep 1996
-
$59.10M(-7.7%)
Jun 1996
-
$64.00M(+0.9%)
Mar 1996
-
$63.40M(-3.2%)
Dec 1995
$65.50M(+221.1%)
$65.50M(+8.3%)
Sep 1995
-
$60.50M(+216.8%)
Mar 1995
-
$19.10M(-6.4%)
Dec 1994
$20.40M
$20.40M(+5.2%)
Sep 1994
-
$19.40M(+158.7%)
Jun 1994
-
$7.50M(+2.7%)
Mar 1994
-
$7.30M

FAQ

  • What is Ligand Pharmaceuticals Incorporated annual total liabilities?
  • What is the all time high annual total liabilities for Ligand Pharmaceuticals Incorporated?
  • What is Ligand Pharmaceuticals Incorporated annual total liabilities year-on-year change?
  • What is Ligand Pharmaceuticals Incorporated quarterly total liabilities?
  • What is the all time high quarterly total liabilities for Ligand Pharmaceuticals Incorporated?
  • What is Ligand Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?

What is Ligand Pharmaceuticals Incorporated annual total liabilities?

The current annual total liabilities of LGND is $111.33M

What is the all time high annual total liabilities for Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated all-time high annual total liabilities is $727.68M

What is Ligand Pharmaceuticals Incorporated annual total liabilities year-on-year change?

Over the past year, LGND annual total liabilities has changed by +$25.03M (+29.00%)

What is Ligand Pharmaceuticals Incorporated quarterly total liabilities?

The current quarterly total liabilities of LGND is $109.90M

What is the all time high quarterly total liabilities for Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated all-time high quarterly total liabilities is $1.41B

What is Ligand Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?

Over the past year, LGND quarterly total liabilities has changed by +$2.55M (+2.38%)
On this page